{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T01:02:45Z","timestamp":1784682165425,"version":"3.55.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Immunology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.humimm.2026.111786","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T20:28:36Z","timestamp":1783024116000},"page":"111786","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The significance of galectin-9 and T-cell immunoglobulin and mucin domain-containing molecule-3 (TIM-3) in patients with chronic lymphocytic leukemia: The role of immune evasion"],"prefix":"10.1016","volume":"87","author":[{"given":"Samia","family":"Hussein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezzat Moustafa","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoda F.","family":"Ebian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad Barakat","family":"Waley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed G.M.","family":"Alshamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahraa I.","family":"Aboafya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basma S.","family":"Elsayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwag","family":"Alsharidah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Atef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha Mahmoud Hamed","family":"Sakr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humimm.2026.111786_bb0085","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1002\/ajh.25595","article-title":"Chronic lymphocytic leukemia: 2020 Update on diagnosis, risk stratification and treatment","volume":"94","author":"Hallek","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.humimm.2026.111786_bb0200","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/cncr.31931","article-title":"Chronic lymphocytic leukemia (CLL) treatment: so many choices, such great options","volume":"125","author":"Sharma","year":"2019","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.humimm.2026.111786_bb0275","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3390\/biology12040541","article-title":"Regulatory mechanisms and reversal of CD8+ T cell exhaustion: a literature review","volume":"12","author":"Zhu","year":"2023","journal-title":"Biology"},{"key":"10.1016\/j.humimm.2026.111786_bb0205","doi-asserted-by":"crossref","first-page":"167","DOI":"10.4149\/neo_2018_180610N385","article-title":"Immunoregulation effects of TIM-3 on tumors","volume":"66","author":"Sheng","year":"2019","journal-title":"Neoplasma"},{"issue":"1","key":"10.1016\/j.humimm.2026.111786_bb0140","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13045-018-0667-4","article-title":"TIM-3 expression and its role in hepatocellular carcinoma","volume":"11","author":"Liu","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.humimm.2026.111786_bb0255","first-page":"1461","article-title":"The effects of TIM-3 activation on T-cells in gastric cancer progression","volume":"17","author":"Yu","year":"2019","journal-title":"Oncol. Lett."},{"issue":"4","key":"10.1016\/j.humimm.2026.111786_bb0040","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.62347\/WBJL4045","article-title":"The role of glycan-lectin interactions in the tumor microenvironment: immunosuppression regulators of colorectal cancer","volume":"15","author":"Chen","year":"2025","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.humimm.2026.111786_bb0235","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1007\/s10753-017-0549-x","article-title":"Elevated galectin-9 suppresses Th1 effector function and induces apoptosis of activated CD4+ T cells in osteoarthritis","volume":"40","author":"Yang","year":"2017","journal-title":"Inflammation"},{"key":"10.1016\/j.humimm.2026.111786_bb0105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1600792","article-title":"Galectin-9 and TIM-3 in gastric cancer: a checkpoint axis driving T cell exhaustion and Treg-mediated immunosuppression independently of anti-PD-1 blockade","volume":"16","author":"Hill","year":"2025","journal-title":"Front. Immunol."},{"issue":"16","key":"10.1016\/j.humimm.2026.111786_bb0115","doi-asserted-by":"crossref","first-page":"7998","DOI":"10.3390\/ijms26167998","article-title":"Galectin-9\u2014an emerging Glyco-immune checkpoint target for Cancer therapy","volume":"26","author":"Karkempetzaki","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.humimm.2026.111786_bb0245","doi-asserted-by":"crossref","unstructured":"I.M. Yasinska, S.S. Sakhnevych, L. Pavlova, A. Teo Hansen Seln\u00f8, A.M. Teuscher Abeleira, O. Benlaouer, I. Gon\u00e7alves Silva, M. Mosimann, L. Varani, M. Bardelli, R. Hussain, G. Siligardi, D. Cholewa, S.M. Berger, B.F. Gibbs, Y.A. Ushkaryov, E. Fasler-Kan, E. Klenova, V.V. Sumbayev, 2019. The TIM-3-Galectin-9 pathway and its regulatory mechanisms in human breast Cancer, Front. Immunol.10,1594. https:\/\/ doi.org\/https:\/\/doi.org\/10.3389\/fimmu.2019.01594.","DOI":"10.3389\/fimmu.2019.01594"},{"key":"10.1016\/j.humimm.2026.111786_bb0005","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/14737140.2025.2582649","article-title":"Chronic lymphocytic leukaemia in the Middle East: a subgroup analysis from the CREEK study on treatment patterns and outcomes","volume":"26","author":"Abdelmoaty","year":"2026","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.humimm.2026.111786_bb0095","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.humimm.2026.111786_bb0210","first-page":"9","article-title":"Clinico-hematologic profile of chronic lymphocytic leukemia in Egypt: a three-center experience","volume":"89","author":"Shoeib","year":"2021","journal-title":"Med. J. Cairo Univ."},{"key":"10.1016\/j.humimm.2026.111786_bb0150","first-page":"71","article-title":"Role of immunophenotyping in diagnosis of CLL patient at South Egypt Cancer institute","volume":"31","author":"Nagieb","year":"2020","journal-title":"Minia Journal of Medical Research"},{"key":"10.1016\/j.humimm.2026.111786_bb0145","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4103\/azmj.azmj_84_24","article-title":"Flowcytometric evaluation of cluster of differentiation 43 and cluster of differentiation 307a in diagnosis of chronic lymphocytic leukemia","volume":"23","author":"Moustafa","year":"2025","journal-title":"Al-Azhar Assiut Medical Journal"},{"key":"10.1016\/j.humimm.2026.111786_bb0160","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.840616","article-title":"Trends in disease burden of chronic lymphocytic leukemia at the global, regional, and national levels from 1990 to 2019, and projections until 2030: a population-based epidemiologic study","volume":"12","author":"Ou","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.humimm.2026.111786_bb0240","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12938-021-00973-6","article-title":"The global burden and attributable risk factors of chronic lymphocytic leukemia in 204 countries and territories from 1990 to 2019: analysis based on the global burden of disease study 2019","volume":"21","author":"Yao","year":"2022","journal-title":"Biomed. Eng. Online"},{"key":"10.1016\/j.humimm.2026.111786_bb0090","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/ajh.27546","article-title":"Chronic Lymphocytic Leukemia: 2025 Update on the epidemiology, pathogenesis, diagnosis, and therapy","volume":"100","author":"Hallek","year":"2025","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.humimm.2026.111786_bb0075","first-page":"C460","article-title":"Understanding the effect of estrogen on B cells: implications for immune health and autoimmunity","volume":"330","author":"Gunduz","year":"2026","journal-title":"Am. J. Phys. Cell Phys."},{"key":"10.1016\/j.humimm.2026.111786_bb0030","doi-asserted-by":"crossref","first-page":"J187","DOI":"10.1016\/j.jaut.2011.11.012","article-title":"The X chromosome and immune associated genes","volume":"38","author":"Bianchi","year":"2012","journal-title":"J. Autoimmun."},{"issue":"1","key":"10.1016\/j.humimm.2026.111786_bb0190","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40246-018-0185-z","article-title":"The X chromosome and sex-specific effects in infectious disease susceptibility","volume":"13","author":"Schurz","year":"2019","journal-title":"Hum. Genomics"},{"key":"10.1016\/j.humimm.2026.111786_bb0045","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/oemed-2012-100845","article-title":"Lymphoma risk and occupational exposure to pesticides: results of the Epilymph study","volume":"70","author":"Cocco","year":"2013","journal-title":"Occup. Environ. Med."},{"key":"10.1016\/j.humimm.2026.111786_bb0125","doi-asserted-by":"crossref","first-page":"6561","DOI":"10.1182\/blood-2023-174755","article-title":"Not all lymphocytosis is chronic lymphocytic Leukemia (CLL): a retrospective review of patients referred to an academic hematology oncology center for CLL","volume":"142","author":"Kiamos","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.humimm.2026.111786_bb0185","series-title":"Burket's Oral Medicine","first-page":"627","article-title":"Hematologic diseases","author":"Sankar","year":"2021"},{"issue":"22","key":"10.1016\/j.humimm.2026.111786_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13225804","article-title":"Autoimmune hemolytic anemia in chronic lymphocytic leukemia: a comprehensive review","volume":"13","author":"Autore","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.humimm.2026.111786_bb0055","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1111\/jth.14943","article-title":"Platelet function and bleeding in chronic lymphocytic leukemia and mantle cell lymphoma patients on ibrutinib","volume":"18","author":"Dmitrieva","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.humimm.2026.111786_bb0100","doi-asserted-by":"crossref","first-page":"553","DOI":"10.4103\/ejh.ejh_71_25","article-title":"17p deletion and atypical flow cytometry profiles in chronic lymphocytic leukemia: correlation to clinical outcomes, single-center Egyptian study","volume":"50","author":"Hamza","year":"2025","journal-title":"Egypt. J. Haematol."},{"key":"10.1016\/j.humimm.2026.111786_bb0130","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.clml.2017.07.008","article-title":"The clinical Spectrum of hepatic manifestations in chronic lymphocytic Leukemia","volume":"17","author":"Kreiniz","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.humimm.2026.111786_bb0020","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.hemonc.2019.01.004","article-title":"The prevalence and prognostic significance of autoimmune cytopenias in a cohort of Egyptian patients with chronic lymphocytic leukemia","volume":"12","author":"Atef","year":"2019","journal-title":"Hematol. Oncol. Stem Cell Ther."},{"key":"10.1016\/j.humimm.2026.111786_bb0230","first-page":"1019","article-title":"Increased serum levels of Galectin-9 in patients with chronic lymphocytic leukemia","volume":"17","author":"Wdowiak","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.humimm.2026.111786_bb0010","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.853","article-title":"Galectin-9 and myeloid-derived suppressor cell as prognostic indicators for chronic lymphocytic leukemia","volume":"11","author":"Alimu","year":"2023","journal-title":"Immun. Inflamm. Dis."},{"key":"10.1016\/j.humimm.2026.111786_bb0215","first-page":"2269","article-title":"Upregulation of Galectin-9 and PD-L1 immune checkpoints molecules in patients with chronic lymphocytic Leukemia","volume":"18","author":"Taghiloo","year":"2017","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"22","key":"10.1016\/j.humimm.2026.111786_bb0035","doi-asserted-by":"crossref","first-page":"5370","DOI":"10.3390\/cancers15225370","article-title":"Prognostic potential of Galectin-9 mRNA expression in chronic lymphocytic Leukemia","volume":"15","author":"Bojarska-Junak","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.humimm.2026.111786_bb0265","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1332205","article-title":"Galectin-9 in cancer therapy: from immune checkpoint ligand to promising therapeutic target","volume":"11","author":"Zhang","year":"2024","journal-title":"Front. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.humimm.2026.111786_bb0250","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s11033-024-09563-w","article-title":"Galectin-9, a pro-survival factor inducing immunosuppression, leukemic cell transformation and expansion","volume":"51","author":"Y\u0131ld\u0131r\u0131m","year":"2024","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.humimm.2026.111786_bb0050","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1182\/blood.V98.9.2633","article-title":"Clinical significance of CD38 expression in chronic lymphocytic leukemia","volume":"98","author":"Del Poeta","year":"2001","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.humimm.2026.111786_bb0155","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3390\/ijms27010098","article-title":"Association of Galectin-9 soluble immune checkpoint with clinical prognostic markers in patients with chronic lymphocytic Leukemia","volume":"27","author":"Ntsethe","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.humimm.2026.111786_bb0260","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40364-020-00222-3","article-title":"Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia","volume":"8","author":"Yun","year":"2020","journal-title":"Biomark. Res."},{"key":"10.1016\/j.humimm.2026.111786_bb0110","series-title":"Advances in cancer biomarkers: from biochemistry to clinic for a critical revision","first-page":"115","article-title":"The actual role of LDH as tumor marker, biochemical and clinical aspects","volume":"867","author":"Jurisic","year":"2015"},{"key":"10.1016\/j.humimm.2026.111786_bb0195","doi-asserted-by":"crossref","first-page":"23478","DOI":"10.18632\/aging.202343","article-title":"Transforming growth factor beta type 1 (TGF-\u03b2) and hypoxia-inducible factor 1 (HIF-1) transcription complex as master regulators of the immunosuppressive protein galectin-9 expression in human cancer and embryonic cells","volume":"12","author":"Seln\u00f8","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.humimm.2026.111786_bb0080","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1159\/000497208","article-title":"Dysregulated expression of TIM-3 and NKp30 receptors on NK cells of patients with chronic lymphocytic Leukemia","volume":"42","author":"Hadadi","year":"2019","journal-title":"Oncol. Res. Treat."},{"key":"10.1016\/j.humimm.2026.111786_bb0220","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/ejh.12880","article-title":"Frequency and functional characterization of exhausted CD8+ T cells in chronic lymphocytic leukemia","volume":"98","author":"Taghiloo","year":"2017","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.humimm.2026.111786_bb0015","first-page":"257","article-title":"CD4+ T cells are exhausted and show functional defects in chronic lymphocytic Leukemia, Iran","volume":"14","author":"Allahmoradi","year":"2017","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.humimm.2026.111786_bb0165","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202100013R","article-title":"Activated Galectin-9\/TIM-3 promotes Treg and suppresses Th1 effector function in chronic lymphocytic leukemia","volume":"35","author":"Pang","year":"2021","journal-title":"FASEB J."},{"key":"10.1016\/j.humimm.2026.111786_bb0070","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s12026-014-8524-1","article-title":"Regulation of T cell responses by the receptor molecule Tim-3","volume":"59","author":"Gorman","year":"2014","journal-title":"Immunol. Res."},{"key":"10.1016\/j.humimm.2026.111786_bb0120","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.819790","article-title":"Elevated levels of soluble CTLA-4, PD-1, PD-L1, LAG-3 and TIM-3 and systemic inflammatory stress as potential contributors to immune suppression and generalized tumorigenesis in a cohort of south African xeroderma pigmentosum patients","volume":"12","author":"Kgokolo","year":"2022","journal-title":"Front. Oncol."},{"issue":"11","key":"10.1016\/j.humimm.2026.111786_bb0225","doi-asserted-by":"crossref","first-page":"881","DOI":"10.3390\/cimb47110881","article-title":"Expression of TIM-3 and Gal-9 immune checkpoints in chronic lymphocytic Leukemia: the potential role of Interleukin-27","volume":"47","author":"W\u0119drowska","year":"2025","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.humimm.2026.111786_bb0180","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1182\/bloodadvances.2022008405","article-title":"TIM-3 signaling hijacks the canonical Wnt\/\u03b2-catenin pathway to maintain cancer stemness in acute myeloid leukemia","volume":"7","author":"Sakoda","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.humimm.2026.111786_bb0065","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ebiom.2017.07.018","article-title":"The TIM-3-galectin-9 secretory pathway is involved in the immune escape of human acute myeloid Leukemia cells","volume":"22","author":"Gon\u00e7alves Silva","year":"2017","journal-title":"EBioMedicine"},{"issue":"14","key":"10.1016\/j.humimm.2026.111786_bb0060","doi-asserted-by":"crossref","first-page":"7542","DOI":"10.3390\/ijms23147542","article-title":"New Frontiers in monoclonal antibodies for the targeted therapy of acute myeloid Leukemia and myelodysplastic syndromes","volume":"23","author":"Gallazzi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.humimm.2026.111786_bb0170","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1267578","article-title":"TIM-3\/Gal-9 interaction affects glucose and lipid metabolism in acute myeloid leukemia cell lines","volume":"14","author":"Rezaei","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.humimm.2026.111786_bb0270","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejphar.2018.11.019","article-title":"Galectins as potential emerging key targets in different types of leukemia","volume":"844","author":"Zheng","year":"2019","journal-title":"Eur. J. Pharmacol."}],"container-title":["Human Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0198885926001321?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0198885926001321?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:27:05Z","timestamp":1784680025000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0198885926001321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":53,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0198885926001321"],"URL":"https:\/\/doi.org\/10.1016\/j.humimm.2026.111786","relation":{},"ISSN":["0198-8859"],"issn-type":[{"value":"0198-8859","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The significance of galectin-9 and T-cell immunoglobulin and mucin domain-containing molecule-3 (TIM-3) in patients with chronic lymphocytic leukemia: The role of immune evasion","name":"articletitle","label":"Article Title"},{"value":"Human Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humimm.2026.111786","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111786"}}